Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 3
1975 2
1977 6
1978 6
1979 2
1980 4
1981 3
1982 17
1983 23
1984 30
1985 32
1986 22
1987 34
1988 23
1989 24
1990 23
1991 19
1992 23
1993 26
1994 29
1995 31
1996 33
1997 34
1998 39
1999 44
2000 42
2001 34
2002 40
2003 32
2004 33
2005 37
2006 38
2007 32
2008 39
2009 35
2010 58
2011 59
2012 40
2013 40
2014 46
2015 41
2016 24
2017 50
2018 38
2019 41
2020 39
2021 32
2022 29
2023 44
2024 33
2025 31
2026 24
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,460 results

Results by year

Filters applied: . Clear all
Page 1
[Cerebral Malaria].
Ohnishi K. Ohnishi K. Brain Nerve. 2026 May;78(5):611-615. doi: 10.11477/mf.188160960780050611. Brain Nerve. 2026. PMID: 42156057 Review. Japanese.
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y. Matsumura I, et al. Among authors: ohnishi k. Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655. Blood Adv. 2024. PMID: 38968156 Free PMC article. Clinical Trial.
Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors.
Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BJY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, Wei F, Fu L, Zhang J, Kitamura F, Yamashita K, Eto K, Iwagami S, Tsukamoto H, Umemoto T, Masuda M, Nagano O, Satou Y, Saya H, Tan P, Baba H, Ishimoto T. Akiyama T, et al. Among authors: ohnishi k. Cancer Res. 2023 Mar 2;83(5):753-770. doi: 10.1158/0008-5472.CAN-22-1890. Cancer Res. 2023. PMID: 36543251
Takeo Ohnishi, PhD, 1944-2017.
Takahashi A, Mori E, Ohnishi K, Matsumoto H. Takahashi A, et al. Among authors: ohnishi k. Radiat Res. 2017 Oct;188(4):465-467. doi: 10.1667/RROOTO.1. Epub 2017 Aug 2. Radiat Res. 2017. PMID: 28767312 No abstract available.
Environments of B cell development.
Tsuneto M, Kajikhina E, Seiler K, Reimer A, Tornack J, Bouquet C, Simmons S, Knoll M, Wolf I, Tokoyoda K, Hauser A, Hara T, Tani-ichi S, Ikuta K, Grün JR, Grützkau A, Engels N, Wienands J, Yanagisawa Y, Ohnishi K, Melchers F. Tsuneto M, et al. Among authors: ohnishi k. Immunol Lett. 2014 Jan-Feb;157(1-2):60-3. doi: 10.1016/j.imlet.2013.11.011. Epub 2013 Nov 24. Immunol Lett. 2014. PMID: 24284375 Review.
Contribution of Macrophage Polarization to Metabolic Diseases.
Komohara Y, Fujiwara Y, Ohnishi K, Shiraishi D, Takeya M. Komohara Y, et al. Among authors: ohnishi k. J Atheroscler Thromb. 2016;23(1):10-7. doi: 10.5551/jat.32359. Epub 2015 Sep 28. J Atheroscler Thromb. 2016. PMID: 26412584 Free article. Review.
Usefulness of Practitioner-Led Pancreatic Cancer Screening.
Matsumoto K, Kushiyama Y, Izumi A, Ohnishi K, Miura M, Ohuchi Y, Hori I, Nakamura T, Hori K, Koshino K, Kobayashi J, Yoshino N, Hoshino U, Okumura T, Tanimura T, Tanaka S, Tanaka S, Nabika T, Nozu T, Wakatsuki Y, Katayama S, Yoshioka S, Ito K, Uchida A, Yuhara N, Noma H, Isomoto H. Matsumoto K, et al. Among authors: ohnishi k. Diagnostics (Basel). 2022 Sep 19;12(9):2257. doi: 10.3390/diagnostics12092257. Diagnostics (Basel). 2022. PMID: 36140658 Free PMC article.
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Ono T, Okada T, Takahashi N, Minami Y, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Okada M, Tauchi T, Atsuta Y, Ohtake S, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Kiyoi H, Miyazaki Y, Matsumura I. Ono T, et al. Among authors: ohnishi k. Blood Adv. 2026 Aug 25;10(16):5683-5691. doi: 10.1182/bloodadvances.2026019701. Blood Adv. 2026. PMID: 42275565 Free PMC article. Clinical Trial.
1,460 results